Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30204
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWight, Joel C-
dc.contributor.authorKu, Matthew-
dc.contributor.authorGarwood, Melissa-
dc.contributor.authorCarradice, Duncan-
dc.contributor.authorLasica, Masa-
dc.contributor.authorKeamy, Louise-
dc.contributor.authorHawkes, Eliza A-
dc.contributor.authorGrigg, Andrew P-
dc.date2022-
dc.date.accessioned2022-06-23T00:29:17Z-
dc.date.available2022-06-23T00:29:17Z-
dc.date.issued2022-05-16-
dc.identifier.citationLeukemia & Lymphoma 2022; 63(10): 2375-2382en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/30204-
dc.description.abstractIntravenous high-dose methotrexate (HD-MTX) is a critical chemotherapeutic agent in hematological malignancies, however, data are lacking on how to predict and prevent toxicities such as kidney injury. We retrospectively analyzed 539 episodes of HD-MTX (≥1 g/m2) delivered to 144 patients for treatment of prophylaxis of CNS hematological malignancy across three Australian institutions and correlated risk factors with toxicity. Clinically relevant (CTCAE v4.03 grade 2-4) nephrotoxicity occurred on 36 (7%) occasions and was mostly grade 2. Multivariate analysis revealed that doses ≥6 g/m2 (HR 5.02, 95%CI 1.46-17.2, p = 0.01) and interacting/nephrotoxic drugs (HR: 7.15, 91%CI: 2.18-23.512, p = 0.001) were the only factors associated with nephrotoxicity. 48-hour methotrexate level, hypoalbuminemia and increasing age were associated with prolonged clearance but not nephrotoxicity. Mucositis, liver dysfunction and cytopenias were transient and mild in most cases. We have demonstrated that the most common risk factors for nephrotoxicity are modifiable which may assist clinical decision-making when administering this important drug.en
dc.language.isoeng-
dc.subjectMethotrexateen
dc.subjecthematological malignancyen
dc.subjectnephrotoxicityen
dc.titleToxicity associated with high-dose intravenous methotrexate for hematological malignancies.en
dc.typeJournal Articleen
dc.identifier.journaltitleLeukemia & Lymphomaen
dc.identifier.affiliationAustin Healthen
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.affiliationWestern Health, Melbourne, Australiaen
dc.identifier.affiliationBox Hill Hospital, Melbourne, Australiaen
dc.identifier.affiliationTownsville University Hospital, Townsville, Australiaen
dc.identifier.affiliationSt Vincent's Hospital, Melbourne, Australiaen
dc.identifier.affiliationThe University of Melbourne, Melbourne, Australiaen
dc.identifier.affiliationMonash University, Melbourne, Australiaen
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/35575146/en
dc.identifier.doi10.1080/10428194.2022.2074987en
dc.type.contentTexten
dc.identifier.orcid0000-0002-3216-2392en
dc.identifier.orcid0000-0002-9289-1335en
dc.identifier.orcid0000-0002-0376-2559en
dc.identifier.orcid0000-0001-5743-3171en
dc.identifier.pubmedid35575146-
local.name.researcherGrigg, Andrew P
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptClinical Haematology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptClinical Haematology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptClinical Haematology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

34
checked on Nov 22, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.